, L'interleukine 2 en immunothérapie clinique
, ASSIM. Immunologie clinique, 1992.
, , 1990.
,
Collection de la biologie à la clinique -Médecine -Sciences ,
, , 1989.
Pharmacologie Principles of cancer treatment ,
, , 1982.
Cancer chemotherapy and biological response modifiers, 1988. ,
,
, Vomissements anticipés et impératif d'efficacité sur l'émésis dès la première cure de chimiothérapie
, Collection Z chimio, 1991.
,
,
, , 1986.
Pharmacologie clinique, bases de la thérapeutique -2ème édition. Expansion Scientifique Française, 1988. ,
Encyclopédie des cancers-Flammarion médecine-sciences, 1986. HOERNI B. Le médecin généraliste face aux cancers, 1988. ,
Encyclopédie des cancers -Flammarion médecine-sciences, CANCERS Guide clinique, 1986. ,
,
, Rôle du zinc et du sélénium dans la génération des radicaux libres lors des accidents ischémiques du myocarde
,
, Les liposomes en biologie cellulaire et pharmacologie. Collection : Recherches en-Editions INSERM, 1987.
,
Encyclopédie des cancers -Flammarion Médecine sciences, 1986. ,
, Bailliere's Clinical Gastroenterology, vol.2, pp.141-168, 1988.
, Liposomes as Carrier of Mèthyl-GAG, lncreased Antitumor Activity and Reduced Hypoglycemia in Mice
, Oncology, vol.44, issue.4, pp.257-262, 1987.
Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathology study, Lancet, vol.2, issue.4, pp.990-993, 1985. ,
, Monoclonal Antitumor Antibodies for Tumour Detection and Therapy. Behring lnst. Mitt, vol.74, pp.3-13, 1984.
,
, Assessing and counteracting the proxidant effects of anticancer drugs
Current perspectives and challenges in the use of monoclonal antibodies as imaging and therapeutic agents, pp.257-265, 1992. ,
, Advanced Drug Delivery Reviews, vol.1, pp.279-318, 1990.
, Scientists Mobilize To lncrease Supply of Anticancer Drug Taxol. News, vol.2, pp.11-18, 1991.
,
, Les nouveaux traitements anti-prolifératifs
, , pp.13-18, 1992.
Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionospheres ,
, J. Biol. chem, vol.259, pp.9359-9364, 1984.
Psychosocial status in chronic illness. A comparative analysis of six diagnostic g roups ,
, New Engl. J. Med, vol.311, pp.506-511, 1984.
Mechanism of action of the steroid hormones ,
, 12 -CHANG T. M. Induction chemotherapy for advanced head and neck cancers: a literature review. Head and neck surgery, New Engl. J. Med, vol.294, pp.150-159, 1322.
,
, Does immunoscintigraphy serve clinical needs effectively? ls there a future for radioimmunotherapy ?, Eur. J. Nucl. Med, vol.2, pp.205-213, 1992.
The systemic capillary leak syndrome: Appearance of interleukin -2 receptor positive cells during attachs ,
, Ann. Inter. Med, vol.113, pp.475-477, 1990.
Occupational exposure of nursing personnel to antineoplastic agents ,
, Oncology Nursing Forum, vol.12, pp.33-39, 1985.
On the receiving end-patient perception of the side-effects of cancer chemothera py ,
, Eur. J. Cancer Clin. Oncol, vol.12, pp.203-208, 1983.
,
, La biologie moléculaire en cancérologie (Il) -Implications pratiques. Le généraliste, vol.1329, pp.10-14, 1992.
Effects of adriamycin on chronic cardiotoxicity in selenium-deficient rats ,
, Basic Research in Cardiology, vol.87, pp.173-183, 1992.
, Scientific Affairs. Effect of toxic chemicals on the reproductive system
, JAMA, vol.253, pp.3431-3437, 1985.
,
, Accidents d 1 extravasation des chimiothérapies anticancéreuses
, Conc. Med, vol.109, issue.31, pp.2862-2867, 1987.
The neuropsychiatrie effects of treatment with interleukin-2 and LAK cells ,
, Ann. Inter. Med, vol.107, pp.293-300, 1987.
Practical consideratlons in the preparation and administration of cancer chemotherapy ,
, Am. J. 1. V. Therap. Clin. Nutr, pp.6-15, 1983.
Ondansétron : nouvel antiémétique de référence ,
, Cahiers Cancer, pp.23-26, 1991.
5-fluorouracil associated cardiotoxicity, Cancer, pp.1-36, 1988. ,
L'immunothérapie des cancers ,
Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochemical and biophysical research communications, vol.77, pp.797-803, 1977. ,
An outline of anti-emetic treatment ,
, Eur. J. Cancer Clin. Oncol, pp.7-11, 1989.
, Subcell Biochem, vol._lA, pp.363-378, 1989.
,
, , p.64, 1991.
Oxygen toxicity, oxygen radicals, transition metals and disease, Biochem. J, vol.219, pp.1-14, 1984. ,
Self-reductlon of the Iron (Ill) -doxorubicin complex ,
, 32 -HAWTHORN J. The physiological basis of chemotherapy-induced emesis, Clinician, pp.14-20, 1988.
Serotonin antagonists: a new class of antiemetic agents, J. Natl. Cancer lnst, vol.83, pp.613-620, 1991. ,
Relation médecin-malade et décision en cancérologie, Bull.Cancer, vol.74, pp.307-312, 1987. ,
,
The symptomatic control of cytostatic drug-induced emesls. A recent history review ,
, Eur. J. Cancer, pp.2-8, 1990.
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting-A randomize doubleblind study ,
, Eur. J. Cancer, vol.26, pp.311-314, 1990.
,
, Multivesicular Liposomes Containing Cytarabine for Slow-Release SC Administration, Cancer Treatment Reports, issue.5, pp.447-450, 1987.
Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes, Cancer Chemotherapy and Pharmacology, vol.2, issue.4, pp.307-310, 1987. ,
, Effect of Adrlamycin Entrapped by Sulfatide-Contalning Liposomes on Ovarlan Tumor-Bearing Nude Mice
, Biotechnology and supplied biochemistry, issue.5, pp.471-478, 1986.
, La Recherche, vol.20, issue.212, pp.904-913, 1989.
Emesis as a critical problem in chemotherapy ,
, N. Engl. J. Med, vol.305, pp.948-949, 1981.
,
, J. Clin. Oncol, 1920.
,
, Antibody-bearing liposomes : targeting in vivo, Biology of the Cell, pp.41-111, 1983.
Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance ,
, Carcinogenesis, vol.2, issue.7, pp.1283-1287, 1988.
,
, Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice
, J. Infect. Dis, vol.150, pp.278-283, 1984.
lmaging and therapy with monoclonal antibodies in non-hematopoietic tumors ,
, Current Opinion in lmmunology, pp.685-693, 1991.
Tests rapides et anticorps monoclonaux ,
, Tempo Médical, vol.222, pp.5-14, 1986.
,
, Scientific American, vol.243, issue.4, pp.66-76, 1990.
Anxiety and drug tast as predictors of anticipatory nausea in cancer chemotherapy ,
, J. Clin. Oncol, vol.4, pp.224-233, 1986.
,
, J. lmmunol, vol.136, pp.1483-2485, 1988.
Psychologie aspects of the treatment of emesis in cancer nursing ,
, Sernin. in Oncol. Nurs, pp.6-9, 1990.
Cancer : pousser les cellules malignes au suicide ,
, , vol.87, p.6, 1991.
Effects of free and liposome encapsulated taxol on two brain tumors xenografted into nude mice, vol.6, pp.23-28, 1992. ,
,
, , vol.20, pp.458-460, 1991.
,
, La Revue du Praticien-Médecine Générale, issue.172, p.715, 1992.
Inhibition of tumor cell growth in vitro and in vivo by 2-methyl 9-hydroxyellipticinium entrapped within phospholipid vesicles. Biopharmaceutics and drug disposition, vol.1, pp.357-371, 1986. ,
Incidence of delayed cisplatin-induced emesis following acute antiemetic prophylaxis with granisetron-An historical review, Advances in emetic control, pp.19-21, 1990. ,
,
, Médecine/sciences, pp.41-44, 1987.
The control of chemotherapy-induced emesis ,
, Ann. int. Med, vol.95, pp.352-359, 1981.
Overview of Monoclonal Antibodies in the Diagnosis and Therapy of Cancer ,
, Cancer Investigation, vol.2, issue.2, pp.195-209, 1991.
Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, Cancer Treat. Rep, vol.66, pp.1601-1604, 1982. ,
Herpes virus infection in patients with neoplastic disease ,
, Am. J. Med, vol.76, pp.464-478, 1984.
,
, Considérations théoriques sur la qualité de vie des cancéreux traités, Bordeaux Med, pp.577-580, 1984.
, LA CHIMIOTHERAPIE 1.1) GENERALITES
1) LES TOXICITES AIGUES 1.2.1. l) LA TOXICITE HEMATOLOGIQUE 1.2.1.2) LA TOXICITE LYMPHOIDE ET ,
IMMUNOSUPPRESSION 1.2.2.3) LA TOXICITE DIGESTIVE 1.2.2.4) LA TOXICITE CUTANEE ET DES PHAN ERES 1.2.2.5) LA TOXICITE RENALE 1.2.2.6) LA TOXICITE CARDIAQUE 1.2.2. 7) LA NEUROTOXICITE-1.2.2.8) LA TOXICITE HEPATIQUE 1.2.2.9) LA TOXICITE PULMONAIRE 1.2 2.9.1) LES SURINFECTIONS PULMONAIRES 1.2.2.9.2) LES INFILTRATS, vol.38, p.39 ,
URL : https://hal.archives-ouvertes.fr/hal-00875126
, , vol.47, p.48
,
, LES ORGANOPLATINES 1.3.1.7.l) CISPLATINE (CISPLATINE R, CISPLATYLR ) 1.3.1.7.2) CARBOPLATINE (PARAPLATINE R )
, LES ANTIPYRIMIDIQUES 1.3.3.2.1) 5-FLUORO-URACILE (FLUORO-URACILE R ) 1.3.3.2.2) CYTARABINE (ARACYTINE R , CYTARBELR )
, LES AUTRES ANTIBIOTIQUES 1.3.5.1.1) BLEOMYCINE (BLEOMYCINE R ) 1
, LES AUTRES AGENTS ANTICANCEREUX, vol.1
,
, ERS 1.5.1) LES CORRECTIONS DES TROUBLES NUTRITIONNELS ET DIGESTIFS 1.5.1.1) LES SOINS BUCCO-DENTAIRES
,
, LES ANDROGENES 11.1.5) L'ASSOCIATION HORMONE-CYTOTOXIQUE 11. l .5. l) ESTRAMUSTINE CESTRACYTR) 11.1.5.2) PREDNIMUSTINE CSTEREOCYTR )
, ANTl-GLUCOCORTICOIDES 11.2.2) LES ANTl-OESTROGENES 11.2.3) LES ANTl-ANDROGENES 11.2.3.1) CYPROTERONE ACETATE (ANDROCURR ) 11.2.3.2) FLUT AMIDE (EULEXINE R ), LES ANTl-HORMONES 11.2.1) LES
, AROMATASEl, vol.12, p.115
,
,
,
, CANCERS
1) LE CISPLATINE 11. l.1) LA TOXICITE RENALE 11. l .2) LES MODIFICATIONS MORPHOLOGIQUES ET CHIMIQUES AU NIVEAU DU REIN ll.1.3), vol.11 ,
, LA PROTECTION 11.1.5.1) L'HYDRATATION ET LES DIURETIQUES 11.1.5.2) LES COMPOSES SOUFRES
,
2.1) LA ZONE CHEMORECEPTIVE IV.2.2) LES VOIES AFFERENTES IV.2.3) LES CENTRES SUPERIEURS CORTICAUX ,
,
, , vol.6